TheraPb highlighted in PSMA Theranostics session at SNMMI by investigator David Pattison
At the 2025 SNMMI Annual Meeting, Dr. David Pattison presented Lead-212 as a promising alpha-emitter…
AdvanCell Admin26 June 2025
Pb212 PSMA vs Ac225 PSMA from biology to supply Alfred Morgenstern PhD Joint Research Centre Karlsruhe Germany
Source: UroToday PSMA & Beyond: Prof Alfred Morgenstern’s ‘212Pb-PSMA vs 225Ac-PSMA from Supply to Biology’…
AdvanCell awarded $18M in Federal funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate Cancer with Targeted Alpha Therapy’
AdvanCell proudly announces $18M in Federal Funding from the Medical Research Future Fund (MRFF) Frontiers…
DesignQ Developer14 April 2025
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the…
DesignQ Developer10 February 2025
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing Sydney, Australia – 3 February 2025…
DesignQ Developer3 February 2025
AdvanCell Commences Drug Product Manufacture from its Facility in Queensland, Australia
AdvanCell Commences Drug Product Manufacture from its Facility in Queensland, Australia October 8th, 2024, SYDNEY…
DesignQ Developer8 October 2024
AdvanCell Recognised in Good Design Award Australia 2024
AdvanCell Recognised in Australia’s International Good Design Awards for Excellence in Design and Innovation September…
DesignQ Developer20 September 2024
UroToday: Oliver Sartor MD interviews AdvanCell CMO Anna Karmann MD PhD on the current state and future of radiopharmaceuticals and the advantages of Lead-212
Source: UroToday Lead-212 Radiopharmaceuticals: Advancing Targeted Alpha Therapy in Oncology - Anna Karmann Oliver Sartor…
DesignQ Developer30 August 2024
AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer
AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer January 4, 2024 - SYDNEY,…
DesignQ Developer4 January 2024
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of ²¹²Pb-ADVC001 in Metastatic Prostate Cancer
AdvanCell Announces First Patient Dosed in Phase I/II TheraPb Clinical Trial of 212Pb-ADVC001 in Metastatic…
DesignQ Developer8 November 2023
